OR WAIT null SECS
September 30, 2022
FDA has approved Relyrio as a once-to-twice daily treatment for patients with ALS.
Citius and the University of Pittsburgh will investigate I/ONTAK in combination with pembrolizumab for treatment of recurrent or metastatic solid tumors.
September 28, 2022
The collaboration will use Octagon’s functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.
The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.
September 27, 2022
Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.
EC has approved Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss.
September 21, 2022
FDA granted accelerated approval to Skysona (elivaldogene autotemcel), which is designed to slow the progression of neurologic dysfunction in adolescents with CALD.
Lonza has expanded its HPAPI multipurpose suite for payload-linker manufacturing.
Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.
September 20, 2022
CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.